
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type …
Mar 29, 2025 · Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months.
The Emerging Threat of H5N1 to Human Health | New England …
Dec 31, 2024 · Against this background, more humans have come into contact with HPAI A(H5N1). Investigators now report in the Journal a series of human cases from the United States and Canada. 2,3 The former ...
Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis
Mar 5, 2025 · 4 Kirby Institute, University of New South Wales Sydney, Kensington, Australia 5 University of Sydney, Sydney 6 Royal Women’s Hospital, Parkville, VIC, Australia
Management of Insomnia | New England Journal of Medicine
Jul 17, 2024 · Insomnia is common and frequently occurs with other disorders. First-line cognitive behavioral therapy with or without medication can produce rapid, sustained alleviation of insomnia symptoms.
Tirzepatide for Obesity Treatment and Diabetes Prevention | New …
Nov 13, 2024 · During the 17-week off-treatment period, an additional 8 participants who received tirzepatide had adjudication-confirmed type 2 diabetes, for a total of 18 participants (2.4%) with new type 2 ...
Primary Results of the INSEMA Trial - The New England Journal of …
Dec 12, 2024 · A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast 2012;21:678-681. Crossref
The Physiology of Hunger | New England Journal of Medicine
Jan 22, 2025 · New knowledge of the physiology of hunger offers new possible therapeutic targets to modulate food intake in pathologic conditions, including obesity and anorexia nervosa. ... New England Journal ...
Antibiotic Treatment for 7 versus 14 Days in Patients with …
Nov 20, 2024 · In the absence of evidence to guide clinical practice, recommendations regarding treatment duration for patients with bloodstream infection are variable, 16-18 with median durations of 14 days or ...
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic …
Dec 7, 2024 · Integrating Blinatumomab in the Frontline Treatment in B-Cell Acute Lymphoblastic Leukemia: A New Era in Therapeutic Management, Journal of Clinical Medicine, 14, 6, (2055), (2025). https://doi ...
Bacterial Vaginosis — Time to Treat Male Partners | New England …
Mar 5, 2025 · Bacterial vaginosis, the most common cause of vaginal discharge in reproductive-age women,1 is associated with multiple consequential adverse outcomes, including an increased risk of adverse birth ...